The extension has been sought by the Company as it is in the process of the obtaining requisite approvals for the Scheme of Amalgamation and Arrangement between Neuland Laboratories (Transferee Company) and Neuland Health Sciences(First Transferor Company) and Neuland Pharma Research (Second Transferor Company) and their respective Shareholders and Creditors ('Scheme'), filed with the Hon'ble National Company Law Tribunal and the timelines involved for the proposed merger.